Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit. read more

Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future... read more

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was... read more

Privo Technologies expands to a new 3000 square foot facility just outside of Boston, MA. Located at 200 Corporate... read more

BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer... read more

Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support... read more

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions... read more

The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists... read more